Benjamin Hohl, CFO: Enliven Therapeutics ELVN Sell · Filed 24/10/30

Trade details

Type: Insider sale
Amount: $159,544
Shares · price: 5,600 sh · $28.49 a share
Held after: 650 sh
Stock: Enliven Therapeutics ELVN
Person: Benjamin HohlCFO
Trade date: 24/10/28
Filed: 24/10/30
Days to filing: 2 days

Sold 89.6% of holdings

Share of holding sold: 89.6%

Enliven Therapeutics trades, last 26 weeks

What else happened in Enliven Therapeutics around then

Filed or reported within 30 days of the trade day · 24/09/28~24/11/27

Benjamin Hohl's recent trades

Benjamin HohlCFO
Planned sale10b5-1 planEnliven Therapeutics
Planned sale10b5-1 plan
Enliven Therapeutics
ELVN
$591.2K
12,036 sh
$591.2K
Filed 09/17
Traded 09/17
Benjamin HohlCFO
Sell10b5-1 planEnliven Therapeutics
Sell10b5-1 plan
Enliven Therapeutics
ELVN
$149.2K
3,401 sh
$149.2K
Filed 06/22
Traded 06/17
Benjamin HohlCFO
Sell10b5-1 planEnliven Therapeutics
Sell10b5-1 plan
Enliven Therapeutics
ELVN
$59K
1,379 sh
$59K
Filed 06/22
Traded 06/17
Benjamin HohlCFO
Sell10b5-1 planEnliven Therapeutics
Sell10b5-1 plan
Enliven Therapeutics
ELVN
$55.4K
1,238 sh
$55.4K
Filed 06/22
Traded 06/17
Benjamin HohlCFO
Planned sale10b5-1 planEnliven Therapeutics
Planned sale10b5-1 plan
Enliven Therapeutics
ELVN
$768.2K
18,054 sh
$768.2K
Filed 06/17
Traded 06/17

Benjamin Hohl, CFO — sold $159.5K of Enliven Therapeutics ELVN · 89.6% of holdings · 10b5-1 plan | Whalegun